The Prevalence of Stimulant and Antidepressant Use by Australian Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Major Depressive Disorder: A National Survey
Restricted accessResearch articleFirst published online March, 2017
The Prevalence of Stimulant and Antidepressant Use by Australian Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Major Depressive Disorder: A National Survey
To identify the prevalence of stimulant and antidepressant medication use by children and adolescents with symptoms meeting the criteria for attention-deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) in Australia. To identify factors associated with stimulant and antidepressant use by children and adolescents in Australia.
Methods:
Data are from a nationally representative sample of 4- to 17-year-olds (n = 6310). Parents completed the Diagnostic Interview Schedule for Children—Version IV (DISC-IV) and the Strengths and Difficulties Questionnaire. Eleven- to 17-year-olds completed a self-report version of the DISC-IV MDD module. Interviewers recorded prescribed medications used by participants in the previous 2 weeks.
Results:
During a 2-week period, 1.3% of all 4- to 17-year-olds and 13.7% of those with symptoms meeting the criteria for ADHD had used stimulant medication, while 0.9% of all 4- to 17-year-olds and 13.4% with MDD had used antidepressants. In total, 22.6% of those using stimulant medications and 57.7% using antidepressant medications did not have symptoms meeting criteria for ADHD or MDD, respectively. Among 11- to 17-year-olds, 5.6% of those with adolescent-only-reported MDD, 10.9% of those with parent/carer-only-reported MDD, and 25.7% of those with MDD reported by both parents/carers and adolescents were using antidepressant medications.
Conclusions:
Only a minority of 4- to 17-year-olds with ADHD and MDD were being treated with stimulant or antidepressant medication. The percentage of adolescents with MDD using antidepressant medications varied depending on whether adolescents, parents/carers, or both identified the presence of MDD. This highlights the importance of using information from both these informants when assessing and treating adolescent depressive disorder.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
3.
AngoldA, ErkanliA, EggerHL, CostelloEJ: Stimulant treatment for children: A community perspective. J Am Acad Child Adolesc Psychiatry, 39:975–984, 2000.
4.
Australian Bureau of Statistics: Australian Demographic Statistics, June2013. Canberra, 2014, Cat. 3101.0.
5.
Australian Commission on Safety and Quality in Health Care: Australian Atlas of Healthcare Variation. 2015. Available at www.safetyandquality.gov.au/atlas/ (accessed March10, 2016).
6.
FegertJM, KolchM, ZitoJM, GlaeskeG, JanhsenK: Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol, 16:197–206, 2006.
7.
FisherPW, ShafferD, PiacentiniJC, LapkinJ, KafantarisV, LeonardH, HerzogDB: Sensitivity of the Diagnostic Interview Schedule for Children, 2nd edition (DISC-2.1) for specific diagnoses of children and adolescents. J Am Acad Child Adolesc Psychiatry, 32:666–673, 1993.
8.
FroehlichTE, LanphearBP, EpsteinJN, BarbaresiWJ, KatusicSK, KahnRS: Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med, 161:857–864, 2007.
9.
GaleraC, PingaultJB, MichelG, BouvardMP, MelchiorM, FalissardB, BoivinM, TremblayRE, CoteSM: Clinical and social factors associated with attention-deficit hyperactivity disorder medication use: Population-based longitudinal study. Br J Psychiatry, 205:291–297, 2014.
10.
GoodmanR: The Strengths and Difficulties Questionnaire: A research note. J Child Psychol Psychiatry, 38:581–586, 1997.
11.
GoodmanR: Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry, 40:1337–1345, 2001.
12.
GreenH, McGinnityÁ, MeltzerH, FordT, GoodmanR: Mental Health of Children and Young People in Great Britain, 2004. Houndmills (Basingstoke), Palgrave Macmillan, 2005.
13.
HafekostJ, LawrenceD, Boterhoven de HaanK, JohnsonSE, SawS, BuckinghamWJ, SawyerMG, AinleyJ, ZubrickSR: Methodology of Young Minds Matter: The second Australian Child and Adolescent Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry, 2015 [Epub ahead of print]; DOI: 10.1177/0004867415622270.
14.
HawesDJ, DaddsMR: Australian data and psychometric properties of the Strengths and Difficulties Questionnaire. Aust N Z J Psychiatry, 38:644–651, 2004.
15.
HetrickSE, McKenzieJE, CoxGR, SimmonsMB, MerrySN: Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev, 11:CD004851, 2012.
16.
HodgkinsP, SasaneR, MeijerWM: Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: Incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther, 33:188–203, 2011.
17.
IpserJC, SteinDJ, HawkridgeS, HoppeL: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev, 3:Cd005170, 2009.
18.
JensenPS, KettleL, RoperMT, SloanMT, DulcanMK, HovenC, BirdHR, BauermeisterJJ, PayneJD: Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry, 38:797–804, 1999.
19.
KarangesEA, StephensonCP, McGregorIS: Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: Focus on children, adolescents and prescriber specialty. Aust N Z J Psychiatry, 48:917–931, 2014.
20.
LawrenceD, JohnsonS, HafekostJ, Boterhoven De HaanK, SawyerM, AinleyJ, ZubrickSR: The Mental Health of Children and Adolescents. Report on the second Australian Child and Adolescent Survey of Mental Health and Wellbeing. Canberra (ACT), 2015.
21.
McCarthyS, WiltonL, MurrayML, HodgkinsP, AshersonP, WongIC: The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr, 12:78, 2012.
22.
McDermottB, BaigentM, ChanenA, FraserL, GraetzB, HaymanN, NewmanL, ParikhN, PeirceB, ProimosJ, SmalleyT, SpenceS, beyondblue Expert Working Committee: Clinical practice guidelines: Depression in adolescents and young adults. Melbourne (Australia), 2010.
23.
MurrayML, de VriesCS, WongIC: A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child, 89:1098–1102, 2004.
24.
NICE: Depression in children and young people: Identification and management. NICE Clinical Guideline 28. London, UK: National Collaborating Centre for Mental Health, 2015.
25.
NICE: Attention deficit hyperactivity disorder: Diagnosis and management. NICE Clinical Guideline 72. London, UK: National Collaborating Centre for Mental Health, 2016.
26.
OlfsonM, HeJP, MerikangasKR: Psychotropic medication treatment of adolescents: Results from the National Comorbidity Survey-Adolescent Supplement. J Am Acad Child Adolesc Psychiatry, 52:378–388, 2013.
27.
PageE, Kemp-CaseyA, KordaR, BanksE: Using Australian Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: Challenges and approaches. Public Health Res Pract, 25:e2541546, 2015.
28.
PringsheimT, LamD, PattenSB: The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol, 21:537–543, 2011.
29.
Psychotropic Expert Group: Therapeutic Guidelines: Psychotropic. 2013. Available at www.tg.org.au/?sectionid=48 (accessed December22, 2015).
30.
SawyerMG, ReyJM, GraetzBW, ClarkJJ, BaghurstPA: Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust, 177:21–25, 2002.
31.
ShafferD, FisherP, LucasCP, DulcanMK, Schwab-StoneME: NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry, 39:28–38, 2000.
32.
StataCorp: Stata Statistical Software: Release 14. College Station (TX), StataCorp LP, 2015.
33.
StoreboOJ, RamstadE, KroghHB, NilausenTD, SkoogM, HolmskovM, RosendalS, GrothC, MagnussonFL, Moreira-MaiaCR, GilliesD, Buch RasmussenK, GauciD, ZwiM, KirubakaranR, ForsbolB, SimonsenE, GluudC: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev, 11:CD009885, 2015.
34.
TaylorD, PatonC, KapurS: The Maudsley Prescribing Guidelines in Psychiatry, 12th edition. West Sussex, UK: Wiley-Blackwell, 2015.
35.
ThomasR, MitchellGK, BatstraL: Attention-deficit/hyperactivity disorder: Are we helping or harming?. BMJ, 347:f6172, 2013.
36.
VisserSN, BitskoRH, DanielsonML, PerouR, BlumbergSJ: Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep, 59:1439–1443, 2010.
37.
VolkersAC, HeerdinkER, van DijkL: Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001–2005). Pharmacoepidemiol Drug Saf, 16:1054–1062, 2007.
38.
WijlaarsLP, NazarethI, PetersenI: Trends in depression and antidepressant prescribing in children and adolescents: A cohort study in The Health Improvement Network (THIN). PLoS One, 7:e33181, 2012.
39.
WolraichML, McKeownRE, VisserSN, BardD, CuffeS, NeasB, GerykLL, DoffingM, BottaiM, AbramowitzAJ, BeckL, HolbrookJR, DanielsonM: The prevalence of ADHD: Its diagnosis and treatment in four school districts across two states. J Atten Disord, 18:563–575, 2014.
40.
World Health Organisation: WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index 2015. 2015. Available at www.whocc.no/atc_ddd_index/ (accessed December22, 2015).
41.
ZitoJM, TobiH, de Jong-van den BergLT, FegertJM, SaferDJ, JanhsenK, HansenDG, GardnerJF, GlaeskeG: Antidepressant prevalence for youths: A multi-national comparison. Pharmacoepidemiol Drug Saf, 15:793–798, 2006.
42.
ZuvekasSH, VitielloB: Stimulant medication use in children: A 12-year perspective. Am J Psychiatry, 169:160–166, 2012.
